Thomas Weisel Starts Lexicon (LXRX) at Overweight, $2.50 Price Target
More News related to LXRX
- Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
- Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
- Skymark Research Initiates Independent Research Coverage on Lexicon Pharmaceuticals, Inc.
- Unusual 11 Mid-Day Movers 01/20: DEAR, TIBB, DIET, PONE Higher; WAVX, CADC, AXU, STEC Lower
- Morning Movers 01/20: DEAR, TIBB, LXRX, CTZN, PONE, CREE Higher; VRS, NEXM, AXU, SUPX Lower
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Thomas Weisel initiates coverage on Lexicon Pharmaceuticals (Nasdaq: LXRX) with an Overweight rating and a $2.50 price target.
With shares of Lexicon closing at $1.60 today (up 6.7%), the firm's new price target represents potential upside of about 56%.
Click here to see all the analyst action on shares of Lexicon.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
